Celestica Inc. (TSE:CLS – Get Free Report) (NYSE:CLS)’s stock price passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$102.46 and traded as high as C$131.08. Celestica shares last traded at C$129.42, with a volume of 737,865 shares trading hands.
Analysts Set New Price Targets
CLS has been the topic of a number of recent analyst reports. Barclays upgraded Celestica to a “strong-buy” rating in a research note on Tuesday, November 5th. UBS Group raised shares of Celestica to a “hold” rating in a research report on Friday, November 22nd.
Read Our Latest Analysis on Celestica
Celestica Stock Up 9.1 %
Insider Buying and Selling
In other Celestica news, Director Robert Andrew Mionis sold 60,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of C$110.13, for a total value of C$6,607,522.80. Also, Director Leila Wong sold 600 shares of Celestica stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of C$97.68, for a total value of C$58,605.18. In the last 90 days, insiders sold 239,854 shares of company stock valued at $24,640,647. 1.00% of the stock is owned by insiders.
About Celestica
Celestica Inc provides supply chain solutions in North America, Europe, and Asia. It operates through two segments: Advanced Technology Solutions, and Connectivity & Cloud Solutions. The company offers a range of product manufacturing and related supply chain services, including design and development, new product introduction, engineering services, component sourcing, electronics manufacturing and assembly, testing, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics, asset management, product licensing, and after-market repair and return services.
Featured Stories
- Five stocks we like better than Celestica
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How to Plot Fibonacci Price Inflection Levels
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Expert Stock Trading Psychology Tips
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Celestica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celestica and related companies with MarketBeat.com's FREE daily email newsletter.